Loading...
Market
Will a clinical trial for HIV treatment using wildtype CCR5 stem cells be announced by June 30, 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
ClinicalTrials.gov and official announcements from research institutions
Story
NatureMedicine: Patient Achieves HIV Remission with Wildtype CCR5 Stem Cells
Sep 5, 2024, 06:30 PM
A male patient has achieved durable HIV remission after receiving an allogenic hematopoietic stem cell transplant from a donor with wildtype CCR5 cells, according to a case study by NatureMedicine. This marks the first remission with wildtype CCR5 cells. The case study highlights the potential of using stem cells from individuals who naturally lack CCR5 receptors to cure HIV. This development follows controversial research by He Jiankui, a Chinese professor who used CRISPR to edit the genomes of two babies to provide them with natural resistance to HIV, which raised significant ethical concerns.
View original story
Similar markets
Significant reduction in HIV levels (over 1000-fold) • 25%
Moderate reduction in HIV levels (100-1000 fold) • 25%
Minimal reduction in HIV levels (less than 100 fold) • 25%
No significant reduction in HIV levels • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Pfizer • 25%
Johnson & Johnson • 25%
Gilead Sciences • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
ChariteBerlin • 25%
University of California • 25%
Harvard University • 25%
Other • 25%
United States • 25%
Europe • 25%
Asia • 25%
Other • 25%
